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ABSTRACT
Sclerostin is a potent inhibitor of Wnt signaling and bone formation. However, there is currently no information on the relation of
circulating sclerostin levels to age, gender, or bone mass in humans. Thus we measured serum sclerostin levels in a population-based
sample of 362 women [123 premenopausal, 152 postmenopausal not on estrogen treatment (ET), and 87 postmenopausal on ET] and
318 men, aged 21 to 97 years. Sclerostin levels (mean SEM) were significantly higher in men than women (33.3 1.0pmol/L versus
23.7 0.6pmol/L, p<.001). In pre- and postmenopausal women not on ET combined (n¼275) as well as in men, sclerostin levels were
positively associated with age (r¼0.52 and r¼0.64, respectively, p<.001 for both). Over life, serum sclerostin levels increased by 2.4-
and 4.6-fold in the women and men, respectively. Moreover, for a given total-body bone mineral content, elderly subjects (age   60
years) had higher serum sclerostin levels than younger subjects (ages 20 to 39 years). Our data thus demonstrate that (1) men have
higher serum sclerostin levels than women, (2) serum sclerostin levels increase markedly with age, and (3) compared with younger
subjects, elderly individuals have higher serum sclerostin levels for a given amount of bone mass. Further studies are needed to define
the cause of the age-related increase in serum sclerostin levels in humans as well as the potential role of this increase in mediating the
known age-related impairment in bone formation.  2011 American Society for Bone and Mineral Research.
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Introduction
C
onsiderable work over the past decade has established the
Wnt/b-catenin signaling pathway as a major regulator of
bone mass.
(1,2) Activation of this pathway results in an expansion
of osteoprogenitor cells as well as reduced apoptosis of mature
osteoblasts, leading to increased bone formation and potentially
marked increases in bone mass.
(1,2) The effects of Wnt ligands on
the canonical signaling pathway involving b-catenin signaling
are mediated by binding of these ligands to a seven-trans-
membrane domain-spanning frizzled receptor and either of two
coreceptors, low-density lipoprotein receptor–related proteins
(LRP) 5 or 6.
(1,2)
Sclerostin is a secreted Wnt antagonist produced almost
exclusively byosteocytes that regulates bone massby binding to
LRP5 and LRP6 to inhibit the canonical Wnt/b-catenin signaling
pathway.
(1,3–6) The biologic importance of sclerostin in humans
is highlighted by sclerosteosis and van Buchem disease, two
genetic diseases associated with markedly increased bone
mass.
(7–10) Sclerosteosis is caused by a mutation in the gene
encoding sclerostin, SOST, that leads to improper splicing of the
SOST mRNA,
(7,8) whereasvanBuchem disease isduetoadeletion
of an enhancer element downstream of the SOST gene.
(9,10) In
additiontothesehumandiseases,micewithknockoutoftheSost
gene also have increased bone-formation rates at trabecular,
endocortical, and periosteal surfaces, as well as increased bone
mass.
(11) Thus, given the compelling evidence for sclerostin as a
major regulator of Wnt signaling and bone mass, an antiscler-
ostin neutralizing antibody has been developed recently as a
novel anabolic treatment for osteoporosis.
(12)
Despite growing understanding of the basic biology of Wnt
signaling and its regulation by sclerostin, there are currently
sparse data on assessment of circulating sclerostin levels in
humans. Using an in-house Amgen immunoassay (Thousand
Oaks, CA, USA), Mirza and colleagues
(13) demonstrated that
sclerostincouldbemeasuredinperipheralserumandwashigher
in 20 postmenopausal than in an equal number of premeno-
pausal women. These investigators also found that in the
postmenopausal women there were significant negative
correlations between sclerostin levels and the free estrogen
(E)indexandparathyroidhormone(PTH)levels.Inrecentstudies,
we used a commercially available immunoassay (Biomedica,
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373Vienna, Austria) to demonstrate that E treatment decreased
circulating sclerostin levels in women and that selective
elimination of E, but not testosterone (T), production in men
resulted in increased serum sclerostin levels.
(14) In addition,
Gaudio and colleagues
(15) have used the same immunoassay to
demonstrate increased circulating sclerostin levels in long-term
immobilized patients. Thus, given the availability of a validated
immunoassay for sclerostin, we sought in this study to measure
serum sclerostin levels in a population-based sample of women
and men in order to define possible relations of sclerostin levels
to age and gender, as well as bone mass, microstructure, sex
steroid levels, and bone turnover markers.
Methods
Study subjects
We recruited subjects from an age-stratified random sample of
Rochester, MN, residents who were selected using the medical
records linkage of the Rochester Epidemiology Project.
(16) This
population is highly characteristic of the U.S. white population,
but blacks and Asians are underrepresented.
(17) The sample
spanned ages from 21 to 97 years and included 362 women and
318 men. Reflecting the ethnic composition of the community,
98% of the subjects were white. There were 123 premenopausal
women and 239 postmenopausal women; of the postmeno-
pausal women, 87 were on some form of estrogen therapy (ET,
defined as oral or transdermal E preparations with or without a
progestin). All studies were approved by the Mayo Institutional
Review Board, and written informed consent was obtained from
all subjects prior to evaluation.
Study protocol
Subjects were evaluated at the outpatient Clinical Research Unit
following an overnight fast. They consumed their habitual diet
the day prior to study without any dietary restrictions. Following
a blood draw, the subjects underwent the various imaging
procedures described below.
Total-body dual-energy X-ray absorptiometry (DXA)
This study was designed originally to focus on volumetric
quantitative computed tomographic (QCT) parameters and did
not include site-specific DXA measures of the spine or hip.
However, the subjects did have a total-body DXA performed
(Prodigy, GE Medical Systems, Madison, WI, USA) using software
Version 6.10.029. From this, we derived the total-body bone
mineral content (TBBMC) and total-body bone mineral density
(TBBMD). In addition, we were able to obtain the spine region
areal BMD (aBMD) from the total-body scans. We have shown
previously that such scans are equivalent to dedicated lumbar
spineDXAmeasurementsinwomen,withr¼0.92andanerrorin
predicting lumbar spine BMD of 6.5%.
(18)
Central QCT
As described previously,
(16,19) single-energy CT scans were made
at the lumbar spine and proximal femur with a multidetector
Light Speed QX-I Scanner (GE Medical Systems, Wakesha, WI,
USA). Calibration standards scanned with the patient were used
to convert CT numbers directly to equivalent volumetric BMD
(vBMD) in mg/cm
3.
(20) To study age- and sex-specific structural
changes in bone mineral distribution and structure, we
developed software for the analysis of bone structure, geometry,
and volumetric density from the CT images, specific details of
which have been described previously.
(19) To validate our
image-processing algorithm, we made 10 scans of the European
spine phantom, which is composed of hydroxyapatite.
(21) The
correlation between bone density results determined by our
algorithm and that of the spine phantom was r¼0.998; using
scans of L2 from the phantom over 10 days, vBMD was estimated
to have a coefficient of variation (CV) of 0.7%.
HRpQCT
Details regarding the high-resolution peripheral quantitative
computed tomographic (HRpQCT) imaging used in this cohort
have been reported previously
(22) and are summarized briefly
here. Owing to the lack of availability of this new instrument
initially, the HRpQCT measurements were done about 2 years
after the other measurements. The HRpQCT scans were obtained
in 237 (86%) of the 275 women not on ET used in this study
(107 premenopausal women and 130 postmenopausal women)
and in 282 (89%) of the 318 men. The nondominant wrist (or in
the case of a prior wrist fracture, the nonfractured wrist) was
scanned using a prototype of the XtremeCT (Scanco Medical AG,
Bassersdorf, Switzerland). The in vivo measurement protocol
included the acquisition of a 3D stack of 116 high-resolution QCT
slices at the distal end of the radius using an effective energy of
40keV, slice thickness of 89mm, field of view of 90mm, image
matrix of 1024 1024 pixels, and pixel size of 89mm.
The processing and analysis of the images also have been
described extensively and validated.
(23–26) Briefly, bone volume/
total volume (BV/TV) is first derived from the trabecular vBMD.
Recognizing that individual trabeculae will not be resolved
at their correct thickness owing to partial-volume effects, a
thickness-independent structure extraction is employed to
assess trabecular microarchitecture. To this end, the 3D ridges
(the center points of the trabeculae) are detected in the gray-
level images,
(24) and trabecular number (Tb.N, 1/mm) then is
taken as the inverse of the mean spacing of the ridges.
(25)
Trabecular thickness (Tb.Th, mm) then is derived as BV/TV  
Tb.N, and trabecular separation (Tb.Sp, mm) is derived as (1 –
BV/TV)   Tb.N, as is done in standard histomorphometry.
(27)
The validity of this approach has been tested rigorously by
comparing the HRpQCT methodology with 28-mm resolution
micro–computed tomography (mCT),
(26) with very high correla-
tion (correlation coefficients of 0.96–0.99) between the mCT and
HRpQCT measurements. The key point is that HRpQCT resolution
has to be sufficient to adequately resolve the distance between
the trabecular ridges (1/Tb.N, or about 300 to 500mm), not
necessarily to resolve individual trabeculae ( 100mm or less).
Serum measurements
Serum sclerostin levels were measured using a recently available
quantitative sandwich enzyme-linked immunosorbent assay
(ELISA) developed by Biomedica and obtained from ALPCO
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(14,15,28) This assay uses a polyclonal goat anti-
human sclerostin antibody as a capture antibody and a biotin-
labeled mouse monoclonal antisclerostin antibody for detection.
The interassay CV was 4%, and the lower limit of detection was
3.6pmol/L. Results offurther validation of this assayare shown in
Table 1. Thus, spiking of control serum with two known amounts
of a sclerostin standard resulted in values that were 96% and
98%, respectively, of the predicted values. Conversely, serial
dilutions (1:2 and 1:4) of control serum resulted in values that
were 105% and 103%, respectively, of the predicted values
(Table 1). Results for the sclerostin measurements are reported
throughout in picomoles per liter (multiply by 22.7 to convert to
picograms per milliliter).
Serum PTH was measured using a two-site immunoassay for
intact PTH (Diagnostic Products Corporation, Los Angeles, CA,
USA; interassay CV<13%). Serum osteocalcin (OC) was measur-
ed using a two-site immunoradiometric assay (CIS-US, Bedford,
MA, USA; interassay CV¼8%). Serum N-terminal propeptide of
type I collagen (P1NP) was measured by radioimmunoassay
(DiaSorin, Stillwater, MN, USA; interassay CV<9%). Serum bone
alkaline phosphatase (B-ALP) was measured using an immu-
noassay from Quidel Corporation (San Diego, CA, USA; interassay
CV<8%). Serum cross-linked C-telopeptide of type I collagen
(CTX) was measured using an ELISA (Nordic Biosciences, Herlev,
Denmark;interassay CV<10%),and serumtartrate-resistant acid
phosphatase isoform type 5b (TRACP 5b) also was measured by
ELISA (Immunodiagnostic Systems, Scotsdale, AZ, USA; inter-
assay CV<14%). Serum E2 and T were measured using LC-MS/
MS (API 5000, Applied Biosystems-MDS Sciex, Foster City, CA,
USA), as described previously.
(29) Values as low as 1.25pg/mL for
E2 and 1ng/dL for T were detectable by this method, with
interassay CVs of 8% and 6% for E2 and T, respectively. The non–
sex hormone–binding globulin–bound, biologically active (bio)
fraction of E2 and T was measured as described previously
(30);
interassay CVs for each were less than 12%.
Statistical analysis
Sclerostin levels were summarized as means SEMs. Two-
sample t tests were used for comparisons between groups.
Unadjusted and age-adjusted Pearson correlation coefficients
were used to assess relationships between serum sclerostin
levels with the various bone density variables, microstructural
parameters, and biochemical markers. Changes in sclerostin
levels between the ages of 20 and 90 years were based on
predicted values from a linear model. Multivariable linear
regression models were developed to calculate the least-squares
(LS) means of sclerostin after adjusting for TBBMC. A p value of
less than .05 was considered significant. All analyses were
performed using SAS Version 9 (SAS Institute, Cary, NC, USA) and
Splus (TIBCO Corporation, Palo Alto, CA, USA).
Results
Figure 1A shows serum sclerostin levels as a function of age in
pre- and postmenopausal women not on ET combined as well as
postmenopausal women on ET, and Fig. 1B shows the analogous
plot for all men. Sclerostin levels were significantly associated
with age in the pre- and postmenopausal women not on ET
combined (r¼0.52, p<.001) and in the men (r¼0.64, p<.001).
Over life, serum sclerostin levels increased by 2.4- and 4.6-fold in
thewomenandmen,respectively.Sincetherouteofmetabolism
and/or clearance of circulating sclerostin (eg, hepatic versus
renal) is currently unknown, we also adjusted for possible effects
of age-related reductions in creatinine clearance. In this analysis,
the creatinine clearance–adjusted correlations with age were
0.47 and 0.56 in women and men, respectively (p<.001 for
both), and the adjusted increases with age were 2.4- and 4.1-fold
in women and men, respectively.
Comparing the pre- and postmenopausal women not on ET
with the men, we found that serum sclerostin levels were
significantly higher in men than in women (33.3 1.0pmol/L
versus 23.7 0.6pmol/L, p<.001). Among the postmenopausal
women, serum sclerostin levels were significantly lower in the
women on ET than in the women not on ET (22.7 1.2pmol/L
versus 27.8 0.8pmol/L, p<.001; Fig. 1A).
Since sclerostin is produced almost exclusively by osteo-
cytes,
(1,3,5,6) we next examined the relation between serum
sclerostin levels and total-body bone mass, estimated using
TBBMC by DXA. In order to reduce confounding by age, we
separated the subjects into three groups: young (ages 20 to 39
years), middle-aged (40 to 59 years), and elderly (60þ years).
Because of the effects of ET on sclerostin levels noted earlier,
we used only women not on ET in this analysis. As shown in
Fig. 2A, there was no association between TBBMC and serum
sclerostin levels in young women, a modest association was
present in middle-aged women (Fig. 2B), and the strongest
positive correlations were noted in elderly women (Fig. 2C). As
also evident, for a given level of TBBMC, sclerostin levels were
Table 1. Characterization of the Sclerostin Assay by Spiking and Serial Dilutions of Control Serum
Measured sclerostin,
pmol/L
Predicted sclerostin,
pmol/L
Measured as percent
of predicted
Spike
Control serum A 14.8 — —
Control serum Aþ2mL 80 pmol/L standard 20.4 21.3 96%
Control serum Aþ5mL 80 pmol/L standard 30.3 31.2 97%
Serial dilution
Control serum B 16.1 — —
1:2 Dilution 8.5 8.1 105%
1:4 Dilution 4.1 4.0 103%
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evaluate this, we compared serum sclerostin levels adjusted
for TBBMC. These were significantly higher (p<.001) in the
elderly women (29.9 0.9pmol/L) than in the young women
(15.1 1.2pmol/L). Figure 3A–C shows the analogous plots for
serum sclerostin levels versus TBBMC in the young, middle-aged,
and elderly men. As in the case of the women, there was no
association between TBBMC and serum sclerostin levels in
young men (Fig. 3A), a modest association was present in
middle-aged men (Fig. 3B), and the strongest positive correla-
tions were noted in elderly men (Fig. 3C). As for the women,
TBBMC-adjusted sclerostin levels were significantly higher
(p<.001) in the elderly men (45.1 1.2pmol/L) than in the
young men (17.5 1.7pmol/L).
We next assessed the relation between serum sclerostin levels
and bone density and microstructural parameters in the three
groups of women and men, as defined earlier (Table 2). None of
these parameters was correlated with serum sclerostin levels in
the young women. In the middle-aged women, unadjusted and
age-adjusted TBBMD and spine aBMD were positively associated
with serum sclerostin levels. By contrast, the bone density and
microstructural parameters generally were positively associated
with serum sclerostin levels in the elderly women (except Tb.Sp,
which showed an inverse association). The overall pattern was
very similar in the men, with elderly men showing positive
associations of all the bone density and microstructural
parameters with sclerostin levels (again, with the exception of
Tb.Sp, which showed an inverse association).
Table 3 shows the unadjusted and age-adjusted correlations
among biochemical markers of bone turnover, hormone levels,
and sclerostinlevelsinthethree groups.Ofinterest, serumbone-
formation markers (B-ALP and P1NP but not OC) were inversely
associated with sclerostin levels in the elderly women; no
associations were present with the bone-formation markers in
the elderly men. Serum CTX also was inversely associated with
sclerostin levels in the elderly women but not men. Serum E2 or T
levels were not associated with sclerostin levels in any group
other than elderly men, in whom serum E2 and bio E2 levels were
positively correlated with sclerostin levels.
Discussion
In this study, we measured serum sclerostin levels in a
population-based sample of women and men using a com-
mercial immunoassay for sclerostin that has been applied in
previous studies by us
(14) and by others.
(15,28) In addition, we
further validated this assay in our laboratory using spiking and
dilution experiments. Our data demonstrate that serum
sclerostin levels increase markedly with age in women and
Fig. 1. Serum sclerostin levels versus age in (A) women and (B) men. Correlation coefficients are as noted.
Fig. 2. Serum sclerostin levels versus total-body bone mineral content (TBBMC) in young (ages 20 to 39 years), middle-aged (40 to 59 years), and elderly
(60þ years) women. Unadjusted and age-adjusted correlation coefficients are as noted.
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exclusively by osteocytes,
(1,3,5,6) this observation would be
consistent with increased skeletal sclerostin production with
aging in humans (see below). While we cannot exclude the
possibility that the age-related increase in circulating sclerostin
levels is due, at least in part, to reduced clearance of the protein,
the increase in sclerostin levels with age was minimally altered
following adjustment for effects of age-related reductions in
creatinine clearance.
Because of the strong correlation with age, we sought to
minimize the potential confounding effects of age by dividing
our cohort into young, middle-aged, and elderly subjects. Using
TBBMC as a surrogate for total skeletal mass, we found that while
TBBMC was not associated with serum sclerostin levels in young
women or men, TBBMC was positively associated with sclerostin
levels in the elderly subjects of both sexes. Since sclerostin is a
potentinhibitorofbone formation,
(1,3)one mighthavepredicted
the opposite, namely, that serum sclerostin levels would be
inversely associated with TBMMC. The fact that we observed a
similar pattern of lack of association in young subjects and
positive associations in the elderly subjects between serum
sclerostin levels and virtually all the other skeletal parameters
assessed(spineaBMD,QCTvBMD,bonemicrostructuralvariables
by HRpQCT) argues that the correlations we noted were not due
to chance and may reflect changes occurring with aging in
skeletal sclerostin production. Specifically, our data also
demonstrate that for any given TBBMC, and presumably an
equivalent number of osteocytes, serum sclerostin levels are
higher in the elderly compared with the young subjects. This
suggeststhatwithaging,there isincreasedsclerostin production
by individual osteocytes. While our data are consistent with this
hypothesis, further animal and human studies addressing this
important issue are needed. Moreover, whether increased
skeletal sclerostin production with aging explains, at least in
Fig. 3. Serum sclerostin levels versus total-body bone mineral content (TBBMC) in young (ages 20 to 39 years), middle-aged (40 to 59 years), and elderly
(60þ years) men. Unadjusted and age-adjusted correlation coefficients are as noted.
Table 2. Correlation Coefficients (Unadjusted/Age-Adjusted) Between Bone Density and Microstructural Parameters and Serum
Sclerostin Levels
Age group (years)
Women Men
20–39 40–59 60þ 20–39 40–59 60þ
DXA
TBBMD 0.04/0.04 0.29
  /0.34
   0.38
   /0.49
    0.29
 /0.31
   0.13/0.14 0.42
   /0.50
   
Spine BMD 0.14/0.11 0.23
 /0.28
  0.42
   /0.46
    0.22/0.19 0.23
 /0.22
  0.46
   /0.44
   
QCT
FN total vBMD 0.02/0.11 0.08/0.20 0.20
 /0.33
     0.00/0.05 0.13/0.19 0.24
  /0.36
   
FN cortical vBMD 0.09/0.13 0.06/0.17 0.19
 /0.23
   0.01/0.02 0.14/0.20 0.16/0.19
 
FN trabecular vBMD  0.08/0.04 0.09/0.19 0.16/0.34
     0.06/0.00 0.07/0.14 0.26
  /0.42
   
Vertebral trabecular vBMD  0.12/ 0.09 0.04/0.18 0.24
  /0.38
    0.11/0.12 0.02/0.08 0.28
   /0.44
   
Radius HRpQCT
Cortical vBMD  0.00/ 0.01  0.11/ 0.07 0.07/0.14 0.11/0.12 0.17/0.18 0.08/0.25
  
BV/TV  0.07/ 0.08 0.03/0.08 0.25
 /0.29
    0.05/ 0.05 0.08/0.12 0.35
   /0.37
   
Tb.N 0.01/0.02  0.01/ 0.00 0.31
  /0.39
    0.34
  /0.33
   0.13/0.13 0.31
   /0.39
   
Tb.Th  0.07/ 0.09  0.00/0.06 0.18/0.19  0.24/ 0.24 0.00/0.04 0.26
  /0.26
  
Tb.Sp  0.01/ 0.02 0.02/ 0.01  0.29
  / 0.36
     0.24
 / 0.24  0.14/ 0.16  0.35
   / 0.42
   
TBBMD¼total-body bone mineral density; FN¼femoral neck; vBMD¼volumetric BMD; BV/TV¼bone volume/tissue volume; Tb.N¼trabecular
number; Tb.Th¼trabecular thickness; Tb.Sp¼trabecular separation.
 p<.05.
  p<.01.
   p<.001.
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(31)
warrants further investigation.
We also observed that at any age, serum sclerostin levels were
higher in men than in women. The reasons for this are unclear,
but to the extent that circulating sclerostin levels might reflect
total-body skeletal mass, the larger skeleton in men simply may
produce and release more sclerostin into the circulation. We also
found that among postmenopausal women, serum sclerostin
levels were significantly lower in women on ET compared with
women not on ET. This finding is consistent with recent data
from our group
(14) showing that E treatment of postmenopausal
women for 4 weeks leads to a 27% decrease in serum sclerostin
levels. Unlike the findings of Mirza and colleagues,
(13) however,
we did not observe any correlations between serum sclerostin
and estradiol (total or bioavailable) levels in any of the three
groups of women. In fact, in the men, we found the opposite, in
that serum estradiol levels were positively associated with
sclerostin levels. In our recent study involving 59 elderly men,
increases in serum sclerostin levels following combined T and E
deficiency were prevented by E treatment alone but not T
treatment without E.
(14) Thus, while our previous interventional
data clearly demonstrate that E reduces serum sclerostin
levels,
(14) the correlation analyses in this study are not consistent
with this observation, suggesting that there may be additional
confounders in the relationship between E and sclerostin levels
that we may not have accounted for in this analysis.
Given the previously noted effects of sclerostin in inhibiting
bone formation,
(1,3) bone-formation markers would be expected
to be inversely associated with sclerostin levels. This was indeed
the case in the elderly women but not in the men. The reasons
for this gender difference are unclear at present. Since the
specific dose relationship between sclerostin and inhibition of
bone formation is not known, it is possible, for example, that the
higher sclerostin levels in the elderly men (to the extent that
these levels reflect skeletal sclerostin production) might be
beyond some biologic saturation point for sclerostin effects on
bone formation, leading to the lack of any correlation between
these levels and bone-formation markers in the men. Additional
studies assessing the dose relationship between sclerostin levels
(and sclerostin production) and bone formation are needed to
test this hypothesis.
In summary, our study represents the first population-based
assessment of circulating sclerostin levels in women and men
over a broad age range using a well-validated immunoassay.
These findings point to the need for further studies examining
the mechanisms for the age-related increase in serum sclerostin
levels we observed in both sexes and the potential role of
increased skeletal sclerostin production in mediating the known
age-related decrease in bone formation in humans.
(31)
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